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Reduced intracellular accumulation of drugs (due to rapid eﬄux) mediated by the eﬄux pump proteins belonging to ABC (ATP
BindingCassette)andMFS(MajorFacilitators)superfamilyisoneofthemostcommonstrategiesadoptedbymultidrugresistance
(MDR) pathogenic yeasts. To combat MDR, it is essential to understand the structure and function of these transporters so that
inhibitors/modulators to these can be developed. The sequence alignments of the ABC transporters reveal selective divergence
within much conserved domains of Nucleotide-Binding Domains (NBDs) which is unique to all fungal transporters. Recently, the
role of conserved but divergent residues of Candida Drug Resistance 1 (CDR1), an ABC drug transporter of human pathogenic
Candida albicans, has been examined with regard to ATP binding and hydrolysis. In this paper, we focus on some of the recent
advances on the relevance of divergent and conserved amino acids of CaCdr1p and also discuss as to how drug interacts with Trans
Membrane Domains (TMDs) residues for its extrusion from MDR cells.
1.Introduction
ThepathogenicCandidaalbicansaccountsforapproximately
50–60% causes of candidiasis particularly in immuno-
compromised human patients. But the infections caused
by non-albicans species, such as C. glabrata, C. parapsilosis,
C. tropicalis,a n dC. krusei are also common particularly in
neutropenic patients and neonates [1–4]. Of note, recently,
the incidences of albicans and non-albicans species of
Candida acquiring resistance to antifungals (particularly to
azoles) have increased considerably which poses problems
towards its successful chemotherapy [5–7]. On one hand,
to combat antifungal resistance, search for better drugs with
newer targets is underway; on the other hand, Candida cells
have evolved a variety of strategies to develop resistance to
common antifungals.
The main mechanisms of antifungal resistance to azoles
include alterations in ergosterol biosynthetic pathway by
an overexpression of ERG11 gene which encodes the drug
target enzyme 14∝-demethylase or by an alteration in
target enzymes (point mutations) [3, 8, 9]. Reduced intra-
cellular accumulation of drugs (due to rapid eﬄux) is
another prominent mechanism of resistance in Candida cells
[10]. Most commonly, genes encoding drug eﬄux pumps
belonging to ABC (ATP binding cassette) and MFS (Major
Facilitator) superfamilies of proteins are overexpressed in
azole resistant Candida isolates which abrogates intracellular
accumulation leading to enhanced tolerance to drugs (Fig-
ures 1(a) and 1(b)).
2. Efﬂux Pumps
Since ABC and MFS transporters are among the major
players that contribute to azole resistance in clinical isolates
of Candida, there is a spurt in research on all aspects of
these genes and their encoded proteins [6, 7]. In this context,
considerable attention is being paid to the structural and
functional aspects of these proteins, which in turn could
lead to better strategies for designing modulators/inhibitors
of these pumps. The genome of C. albicans possesses 28
ABC and 95 MFS proteins; however, only ABC transporters
CaCdr1p and CaCdr2p and MFS transporter CaMdr1p are
known to be multidrug transporters which play major role
in drug extrusion from resistant strains. In this review, we2 Journal of Amino Acids
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Figure 1: A cartoon representation of (a) ABC and (b) MFS transporters of Candida. The topology of ABC and the MFS transporters
depicted here have the (NBD-TMS6)2 and the (TMS)12 (Transmembrane Segments) arrangements, respectively. The NBDs (Nucleotide-
Binding Domains) of the ABC transporters are responsible for the hydrolysis of ATP, which facilitates drug extrusion while the MFS
transporters utilize proton gradient to expel drugs.
begin with a discussion on the structure and function of
ABC proteins and then focus on the role of some of the
critical amino acid residues of CaCdr1p in drug transport.
F o rb r e v i t y ,w eh a v ee x c l u d e dM F Sd r u gt r a n s p o r t e r sf r o m
our discussion.
3. Structure and Function of
ABC EfﬂuxProteins
ABC proteins are generally made up of two transmembrane
domains (TMDs), each consisting of six transmembrane
segments(TMS)andtwocytoplasmicallylocatednucleotide-
binding domains (NBDs) which precedes each TMD (Fig-
ures 1(a) and 1(b)), [11, 12]. While it appears that several
TMSs associate together to form the substrate binding
site(s), this alone is probably not suﬃcient for substrate
transport across the membrane bilayer. Vectorial transport
of these substrates requires energy from the hydrolysis of
ATP carried out at the NBDs. Given their varied roles
and the greatly diﬀering characteristics of substrates that
members of this superfamily of proteins seem to eﬄux, it
is hardly surprising that despite the overall conservation of
the domain architecture of TMDs, their primary sequences
are signiﬁcantly diﬀerent (Figure 2). On the other hand,
NBDs of ABC transporters which power drug transport are
highly conserved both in terms of primary structure and
architecture (Figure 3).
4.CandidaDrug Resistance 1(CDR1)
CDR1 of C. albicans, the ﬁrst ABC eﬄux pump characterized
in any known pathogenic yeast, was isolated as a gene
implicated in conferring resistance to cycloheximide in
a PDR5 disruptant hypersensitive strain of S. cerevisiae
[13]. CaCDR1 codes for a protein of 1501 amino acid
residues (169.9kDa), with a topology similar to that of
ABC proteins Pdr5p and Snq2p of S. cerevisiae. On the
other hand, its topology mirrors that of STE6,a- m a t i n g
pheromone transporter of S. cerevisiae,a sw e l la so ft h e
human MDR1 and CFTR. Despite a high structural and
functional similarity between CaCdr1p and ScPdr5p, some
distinct functional features tend to distinguish them. For
example, both genes share overlapping speciﬁcities for
cycloheximide and chloramphenicol but CaCDR1 aﬀects
sensitivity to oligomycin while neither ampliﬁcation nor
disruptionofScPDR5alterssusceptibilitiestothismitochon-
drial inhibitor [13]. It is worth mentioning that some of
the close homologues of CaCDR1 in C. albicans are also
functionally distinct. For example, CaCdr2p that exhibits
84% identity with CaCdr1p has a distinct drug resistance
proﬁle [14]. The overexpression or deletion of CaCDR3
and CaCDR4, the homologues of CaCDR1 and CaCDR2
interestingly do not aﬀect drug susceptibilities of yeast cells
[15]. The hydropathy plots of CaCdr1p and CaCdr3p show
that both the proteins have similar topological arrangements
wherethehydrophilicdomaincontainingtheNBDsprecedes
the hydrophobic TMS [16]. The only apparent diﬀerence
between the two proteins appears to be in the C-terminal
where CaCdr3p has an extended loop connecting TM11 and
TM12. In addition, there is stretch of 21 amino acids in
the C-terminal of CaCdr3p which are absent in CaCdr1p
[16]. Keeping in view, the importance of these regions in
drug binding and transport, the subtle diﬀerences in the
primary structures of these proteins could be responsibleJournal of Amino Acids 3
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Figure 2: Sequence logos of CaCdr1p transmembrane segment (TMSs) residues with other fungal PDR transporters. Each logo consists of
stacks of symbols, one stack for each position in the sequence. The scale indicates the certainty of ﬁnding a particular amino acid at a given
position and is determined by multiplying the frequency of that amino acid by the total information at that position. The residues at each
position are arranged in order of predominance from top to bottom, with the highest frequency residue at the top. The height of symbols
within the stack indicates the relative frequency of each amino acid at that position. Colors such as green deﬁnes polar, blue correspond to
basic, red to acidic, black to hydrophobic, and violet represent the amino acids that have polar amide group.
in governing their substrate speciﬁcity, hence only enabling
someofthem(CaCdr1pandCaCdr2p)tobindandtransport
drugs [17, 18].
To study the MDR proteins, a heterologous hyperexpres-
sion system is used where GFP tagged CaCdr1p/CaMdr1p
has been stably overexpressed from a genomic PDR5 locus
in a S. cerevisiae mutant AD1-8u− [19]. The host AD1-
8u− developed by Goﬀeau’s group [20]w a sd e r i v e df r o m
a Pdr1-3 mutant strain with a gain of function mutation
in the transcription factor Pdr1p, resulting in constitutive
hyperinduction of the PDR5 promoter [19]. In previous
studies, we have conﬁrmed that GFP tagging of CaCdr1p
(CaCDR1-GFP)a n dC a M d r 1 p( CaMDR1-GFP) did not
impair its expression and the functional activity of the
proteins [21, 22]. Figure 4 summarizes the strategy used for
the expression of CaCDR1-GFP under ScPDR5 promoter.4 Journal of Amino Acids
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Figure 3: Sequence alignment of the conserved motifs from fungal ABC transporters. Comparison of the sequence alignment of the walker
A, Q-loop, signature C, Walker B, and H-loop motifs of N- and C-terminal NBDs (NBD1 and NBD2) of CaCdr1p with known (a) fungal
and (b) nonfungal ABC transporters. Conserved but unique residues are highlighted.
5. How Does CaCDR1PowerDrug Efﬂux?
The characteristic feature of CaCdr1p or of any other ABC
drug transporter is that they utilize the energy of ATP
hydrolysistotransportvarietyofsubstratesacrosstheplasma
membrane. The conserved NBDs located at the cytoplasmic
p e r i p h e r ya r et h eh u bo fs u c ha na c t i v i t y .T h eN B D so fa l l
ABC transporters, irrespective of their origin and nature
of transport substrate, share extensive amino acid sequence
identity within typical motifs [12]. For example, NBDs of
ABC transporters have a β-sheet subdomain containing the
typical Walker A and Walker B motifs, as an essential feature
of all ATP requiring enzymes [23], along with an α-helical
sub-domain that possesses the conserved ABC signature
sequence. NBD domain sequences possess certain conserved
amino acid stretches, which are considered to be critical
for its functionality [24]. These include: the Walker A, with
a consensus sequence GxxGxGKS/T, where “x” represents
any amino acid, the Walker B motif, that is, hhhhD, where
“h” represents any aliphatic residue, and an ABC signature,
LSGGQQ/R/KQR. Structural and biochemical analyses of
NBDs show that the well-conserved lysine residue of Walker
A motif binds to the β-a n dγ-phosphates of ribonucleotides
and plays a critical role in ATP hydrolysis [24]. Mutations
of this lysine residue have been shown to reduce or abolish
the hydrolysis activity and in some cases impair nucleotide
binding [24]. Interestingly, though N-terminal NBD of
CaCdr1p contains the conserved Walker A (GRPGAGCST)
and B (IQCWD) motifs, and an ABC signature sequence
(VSGGERKRVSIA) [25], the commonly occurring lysineJournal of Amino Acids 5
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Figure 4: Overexpression of CaCdr1p in a heterologous system. (a) Strategy showing the cloning and transformation of CaCDR1-GFP in S.
cerevisiae. (b) Pictorial representation of the host AD1-8u− showing the Deleted ABC pump proteins (pdr5, pdr10, pdr11, pdr15, snq2, yor1,
ycf1) and the hyper expressed CaCDR1-GFP. (c) Topology of CaCdr1p. (d) Localization of CaCdr1-GFP in the host strain AD1-8u−.T h e
rimmed green ﬂuorescent depicts overexpressing GFP tagged CaCdr1p.
residue within the Walker A motif is replaced with a cysteine.
This replacement appears to be a unique feature of N-
terminal NBDs (N-NBD) of most of the known fungal ABC-
type transporters. In addition, degeneracy in Q loop and
Walker B also exist in N-NBDs of all fungal transporters
includinginCaCdr1p.Notably,theC-terminalNBDsdisplay
degeneracy only in signature motifs (discussed later).
To ascertain the role of the uncommon cysteine of
Walker A, active N-NBD of CaCdr1p was cloned and
overexpressed and the soluble domain protein was puriﬁed
and characterized. It was observed that an evolutionarily
divergent Cys193 of Walker A of N-NBD was critical for ATP
hydrolysis. The relative contribution of both the N- and C-
terminal NBDs in ATP binding, hydrolysis, and transporter
activity of native CaCdr1p (full protein) was examined
wherein the atypical Cys193 of Walker A of N-NBD (C193K)
andconservedLys901(K901C)intheWalkerAofC-terminal
NBD (C-NBD) were replaced [26]. The drug resistance
proﬁle of CaCdr1p mutant variant cells harboring C193K
or K901C gave interesting insights into the functioning
of the two NBDs. The cells expressing K901C showed
enhanced hypersensitivity to drugs as compared to C193K
variant which displayed partial sensitivity to select drugs.
These observations clearly established that the two NBDs
respond asymmetrically to the substitution of conserved
residues of their respective Walker A motifs. The functional
asymmetry of NBDs in CaCdr1p was also illustrated in
another study where swapping of NBDs resulted in non-
functional CaCdr1p chimeras and thus suggested that the
two NBDs are not identical and nonexchangeable [27].
Interestingly, in the case of human P-gp, a close homologue
of CaCdr1p, the issue of functional symmetry of two NBDs
remains contentious. Approaches addressing this issue in P-
gp provide data both in favor [28, 29] and against [30–
32] functional asymmetry. This is in contrast with many
other ABC transporters, for which there is evidence that the6 Journal of Amino Acids
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mechanism for ATP hydrolysis by the N-NBD of CaCdr1p the details are discussed in the text.
two NBDs, although highly similar in sequence, may adopt
diﬀerent functional roles in the transport cycle [33].
Any functional asymmetry observed in the intact trans-
porter is probably not entirely due to inherent properties
of the NBD, and presumably also reﬂects either diﬀerences
in the rate of hydrolysis or the eﬀects of interdomain inter-
actions. Two other residues of the N-NBD from CaCdr1p
are also found to be important for domain functioning.
As depicted in Figure 5, the unusual Trp326 in the Walker
B motif of N-NBD, which is unique and conserved in all
fungaltransporters,isimportantforATPbindingandforthe
accompanying conformational change [34]. Thus, although
the mutant with W326A appears capable of ATP hydrolysis,
it does so with a much higher KM value, indicating that
the docking of the substrate in the binding pocket has
been altered by the mutation. However, the protein appears
capable of near-normal function in cells expressing the
full-length protein carrying W326A mutation, implying
that the conformational change that normally occurs upon
ATP docking cannot by itself be responsible for the cross-
talk by the domain with the TMDs. While the highly
conserved Asp327 of N-NBD is shown to be the catalytic
carboxylate in the context of other ABC transporters, in N-
NBD of CaCdr1p, it does not appear to mediate catalysis
via interaction with Mg2+ as is normally expected for
similar transporters [34]. It has been shown that due to
spatial proximity, ﬂuorescence resonance energy transfer
(FRET) takes place between Trp326 of Walker B and MIANS
[2-(4-maleimidoanilino) naphthalene-6-sulfonic acid] on
Cys193 of Walker A motif. These critical amino acids are
positioned within the nucleotide-binding pocket of N-NBD
to bind and hydrolyze ATP. The results show that both
Mg2+ coordination and nucleotide binding contribute to the
formation of the active site. The entry of Mg2+ into the
active site causes the ﬁrst large conformational change that
brings Trp326 and Cys193 in close proximity to each other.
It was also demonstrated that besides Trp326, typical Glu238
in the Q-loop also participates in coordination of Mg2+ by
N-NBD. A second conformational change is induced when
ATP, but not ADP, docks into the pocket. The unique Asn328
does sensing of the γ-phosphate of the substrate in the
extended Walker B motif, which is essential for the second
conformational change that must necessarily precede ATP
hydrolysis.
It has been possible to deduce a picture of the catalytic
mechanism for ATP hydrolysis by the N-NBD of CaCdr1p
(Figure 5). The metal ion approaches the nucleotide binding
pocket and forms a π-stacking interaction with the delo-
calized electron cloud of Trp326 in Walker B. This induces
a large conformational change in the protein, bringing
Cys193, Glu238, Trp326, Asp327, and Asn328 closer into
the nucleotide binding pocket. At this point, the metal ion
is suﬃciently far from the MIANS on Cys193 to have no
eﬀect on its ﬂuorescence intensity. However, Trp326 and
MIANS on Cys193 are within 16 ˚ A of each other at this
point. ATP approaches with its phosphates directed towards
the pocket. As in other ATPases, it may be assumed that
the β and γ-phosphates also coordinately bind the metal
ion and their negative charges are considerably masked. This
is important since in the absence of the metal ion, the
nucleotide does not dock into the active site. While other
residues may also be involved in stabilizing the nucleotide
within the pocket, Asn328 certainly acts as a sensor for the γ-
phosphate. This induces the second conformational changeJournal of Amino Acids 7
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Figure 6: Topology of CaCdr1p and sequence alignment of signature motifs from various ABC transporters. The sequence alignment of
signature motif residues in NBDs with those from other nucleotide-binding domains of some known ABC transporters is shown.
within the protein. Asp327 which acts as a catalytic base
abstracts a proton from a water molecule, that is, part of
the Mg-ATP complex present in the active site. The hydroxyl
ion, thus, formed in turn attacks at the β-phosphate allowing
it to, in turn, abstract a proton from the –SH of Cys193.
The consequence of this is to simultaneously weaken the
phosphodiesterbondbetweenβ-andγ-phosphates,allowing
the latter to leave. Once ATP is hydrolyzed, Asn328 no longer
senses the γ-phosphate, and the conformation relaxes back
to a more open one allowing ADP to leave (Figure 5).
The data thus far unequivocally show that the N-NBD of
CaCdr1p and by extension those of other fungal transporters
have evolved so as to use their unique substitutions to
perform the task of ATP binding and hydrolysis. While it
is not yet clear what evolutionary advantage these typical
sequence variations might provide to the organisms, it is
becoming more and more evident that it has mechanistic
implications for the protein. We are yet to understand
how the N-NBD works in conjunction with the C-NBD to
give rise to a functional drug transporter. Does working in
tandem require the ABC Signature sequence of one NBD to
participate in ATP binding by the other, as is seen in other
ABC transporters? Like in the N-NBDs, the ABC signature
sequences of CaCdr1p and other fungal transporters too
appear to have diverged away from that of other ABC
transporters. Whether this is so as to compensate for the
substitutionsintheirN-NBDsorwhethertheyhaveevolveda
new mechanism for coming together for ATP hydrolysis and
drug eﬄux is a question worth examining.
Signature motifs are other domains which are the
hallmark sequences of NBDs of ABC transporters that
display highly conserved sequences across the evolutionary
scale; however, there are also instances of appearance of
selective divergence within this motif. For example, human
ABC transporters such as TAP [35] and CFTR [36]h a v e
degenerated Signature motifs (Figure 6). In contrast, all the
family members of ABC transporters of fungi, particularly of
PDR subfamily display divergence in their Signature motifs.
Thus, the Signature motif of N-NBD of CaCdr1p is well
conserved but has C-NBD with a degenerated Signature
motif (Figure 6). Our recent analysis revealed that the con-
served and degenerated Signature sequences of the CaCdr1p
are functionally indispensable and cannot be exchanged.
This emphasizes the uncompromised asymmetry that exists
between the NBDs of CaCdr1p and in other yeast ABC
transporters. Similar to other ABC transporters, the well-
conserved serine (S304) and glycine (G306) residues present
in conserved Signature motif of N-NBD are also critical for
the functioning of CaCdr1p. For example, even the sub-
stitution at the equivalent position residues of degenerated
Signature motif of C-NBD with the conserved ones and
vice versa does not support the function of the transporter
[25]. The well-conserved glycine present at fourth position
of Signature motif (LSGGQ) is involved in the ATP catalysis8 Journal of Amino Acids
Table 1: Substrates and inhibitors of CaCDR1 substrates.
Substrates
Fluconazole, ketoconazole, voriconazole, Itraconazole, miconazole, lipids, steroids, R6G,
cycloheximide, rhodamine 123, cerulenin, triﬂuoperazine, nigericin, tamoxifen, verapamil,
cycloheximide, propanil, diuron, linuron, disulﬁram, anisomycin, doxorubicin, 4-nitroquinoline
–N-oxide, benomyl, yohimbine HCl, quinidine, etoposide, chlorobromuron, vinblastine,
tamoxifen, geﬁtinib, ﬂuphenazine, topotecan, daunorubicin, DM-11, AT-12 niguldipine,
dexamethasone, berberine, terbinaﬁne, tritylmazole
[7, 53]
Inhibitors/modulators Milbemycins, enniatin, FK506, FK520, unnarmicins, curcumin, disulﬁram [54–57]
[25, 30, 36–39]. Biochemical analysis revealed that a small
change at this position (G→A) results in steric hindrance
between methyl group of alanine and γ-phosphate of ATP.
If this glycine is exchanged with bulky, charged aspartate
or glutamate, it leads to a complete loss of ATPase and
protein activity [25, 40, 41]. The critical nature of serine
and glycine in WT-CaCdr1p can also be compared with
similar residue of those proteins whose crystal structures
are known. The existing structural information suggests that
the Signature motifs of ABC proteins; Rad50 of Pyrococcus
furiosus, MJ1096 of Methanocaldococcus jannaschii, GlcV
of Sulfolobus solfataricus, Sav1866 of Staphylococcus aureus,
mouse CFTR, HlyB, and MalK of E.coli, are involved in the
head to tail ATPase site formation with the Walker A and
WalkerBmotifsoftheopposite NBDs,sandwichedwithATP
molecules wherein the Signature motif is a “sensor” for an
ATP γ-phosphateintheopposingdomain[24,42–49].Based
on the conserved nature of these motifs, it is reasonable to
speculate that in CaCdr1p, the conserved S304 and G306
of NBD1 probably fall within close proximity of the ATP
binding site. In addition, divergent residues present in C-
NBD Signature region are also equally important and may
be part of the ATPase site as well. However, it still requires
experimental validation.
Additionally, it is shown that in addition to highly
conserved and critical S304 and G306 residues, the equiposi-
tional residues N1002 and E1004 of degenerated Signature
motif of C-NBD of WT-CaCdr1p have also evolved to
be functionally essential. Notably, pairs of residue like
V303, G305 of N-NBD and L1001, V1003, Q1005 of C-
NBD Signature motif though part of otherwise conserved
Signature sequences has apparently no functional relevance.
These residues when replaced with either alanines or with
its equipositional substitutes continued to show phenotypes
similar to cells expressing WT-CaCdr1p.
Functional nonequivalence in the NBDs of ABC proteins
of yeast is the result of variations in the conserved motifs
(Walker A, Walker B, H-loop and Signature motif). These
variations in N-NBD may have evolved in response to
degenerated Signature motif of C-NBD. Thus, in CaCdr1p,
both canonical and noncanonical ATP binding sites are
formed similar to TAP and CFTR proteins. Recently, Ernst
et al. hypothesized that in Pdr5p of S. cerevisiae,o n e
ATP molecule catalyzed at the canonical active site may
be suﬃcient to reset the TMDs whereas the second non-
canonical site (regulatory site) may be engaged to serve
as platform for keeping domains in dimeric form (inward
facing) [49, 50].
6. CaCDR1ExtrudesStructurally
Unrelated Substrates
The range of CaCdr1p substrates varies enormously and
includes structurally unrelated compounds such as azoles,
lipids, and steroids (Table 1). This promiscuity towards
substrates is a characteristic feature of most ABC-type
drug transporters and, hence, makes their functionality all
the more complex to understand. Expectedly, predicting
the residues involved in substrate binding without high-
resolution structural data is a challenge. Yet, using a
combination of biochemical assays along with site-directed
mutagenesis, it has been possible to partially dissect the
substrate binding pockets of CaCdr1p wherein role of some
of the TMS amino acids in drug extrusion is becoming
apparent [17, 18, 21].
7. Natureof SubstrateBinding
ExperimentswithpuriﬁedCaCdr1phaveconclusivelyshown
that ATP binding to CaCdr1p is not a prerequisite for drug
binding and both the mechanisms of drug and ATP binding
result in speciﬁc conformational changes which take place
independent of each other [51]. A direct link between the
ability of CaCdr1p to translocate ﬂuorescent glycerophos-
pholipids and eﬄux drugs has also been demonstrated [51].
Considering chemically diverse substrates which are expelled
by CaCdr1p, the exact number of residues involved in drug
binding and transport is far from understood.
As mentioned earlier, the CaCdr1p was overexpressed as
a GFP-tagged fusion protein in a heterologous hyperexpres-
sion system and was characterized for drugs and nucleotide
binding [52]. Iodoarylazido prazosin (IAAP, a photoaﬃnity
analogue of P-gp substrate, prazosine) and azidopine (a
dihydropyridine photoaﬃnity analogue of P-gp modulator,
verapamil) were shown speciﬁcally to bind with CaCDR1-
GFP. Interestingly, IAAP binding with CaCdr1p-GFP was
competed out by molar excess of nystatin while azidopine
binding could only be competed out by miconazole, thus,
highlighting the possibility of diﬀerent drug binding sites
for the two analogues [52]. Gauthier and coworkers [52]
have also shown that membranes prepared form CaCdr1p
and CaCdr2p expressing cells are capable of binding the
photoaﬃnity analogue of rhodamine 123 (125I) iodoaryl
azido-rhodamine 123 (IAARh123) and that both N-terminal
and C-terminal halves of CaCdr2p contribute to rhodamine
binding [52].Journal of Amino Acids 9
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Figure 7: Cartoon of CaCDR1 protein depicting the location and phenotype of the mutated amino acids. Residues important for the
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To understand the mechanism of drug transport medi-
ated by CaCdr1p, a battery of its mutant variants that
drastically aﬀect various stages of drug extrusion have been
generated (Figure 7). Amino acids of two of the twelve
TMSs of CaCdr1p were subjected to alanine scanning
wherein all the residues were replaced with alanines. The
alanine scanning of TMS 11 of CaCdr1p showed that at
least seven residues which were critical for determining
substrate speciﬁcity and drug transport were clustered on
the hydrophilic face of the α helical projection of TMS11
[18]. In contrast, alanine scanning of TMS 5 highlighted
the importance of all 21 residues in drug transport and
substrate speciﬁcity [17]. Based on the drug susceptibility
pattern, the mutant variants of the TMS 5 could be grouped
into two categories. The mutants belonging to ﬁrst category
exhibited sensitivity to all the tested drugs while the mutants
placed in the other category showed intermediate level of
resistance. While the ATPase activity and drug binding
were largely unaﬀected, rhodamine 6G (R6G) and [3H]
ﬂuconazole (FLC) eﬄux was abrogated in all the mutant
variants. Based on the competition experiments with the
molar excess of substrates during R6G eﬄux, we could
identify residues which may be speciﬁc for interactions with
miconazole (MCZ), itraconazole (ITR), and ketoconazole
(KTC) and those which were common to all the three azoles.
Notably, FLC which is also a substrate of CaCdr1p did not
compete with R6G eﬄux; hence implying that CaCdr1p
has independent binding sites for this azole. All the mutant
variants display uncoupling between ATPase activity and
drugtransport,andthusTMS5ofCaCdr1pnotonlyappears
to impart substrate speciﬁcity but probably also acts as a
communication helix. What constitutes the substrate/drug
binding pocket and how TMS 5 interacts with other helices
of CaCdr1p are some of the issues that remain to be resolved
(Figure 8).
Together, studies so far suggest that the drug binding
sites in CaCdr1p are scattered throughout the protein and
probably more than one residue of diﬀerent helices are
involved in binding and extrusion of drugs. However, there
is still insuﬃcient information available to predict where
exactly the most common antifungals, such as azoles bind
and how they are extruded. However, such studies should
pavethewayforfutureinvestigations relatedtothedynamics
of substrate selection and may improve our approach in the
design of new inhibitors/modulators of drug transporter for
clinical applications.10 Journal of Amino Acids
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Figure 8:HelicalwheelprojectionofTMS5andTMS11ofCaCdr1p.Helicalwheelprojectionoftheproteinsequencewasconstructedbythe
EMBOSSPEPWHEELprogram.Thisdisplaysthesequenceinahelicalrepresentationasiflookingdowntheaxisofthehelix.Thehydrophilic
residues as circles, hydrophobic residues as diamonds. Hydrophobicity is color coded as well: the most hydrophobic residue is green, and
the amount of green is decreasing proportionally to the hydrophobicity, with zero hydrophobicity coded as yellow. Hydrophilic residues are
coded red with pure red being the most hydrophilic residue, and the amount of red decreasing proportionally to the hydrophilicity. The
mutations that aﬀected drug resistance are circled blue.
8. Concluding Remarks
The drug transporters belonging to either ABC or MFS
superfamily of proteins are the main contributors of azole
resistance in pathogenic C. albicans. In this regard, CaCdr1p,
amajorABCmultidrugtransporter,hasbeenwidelystudied.
CaCdr1p like its sister fungal homologues is unique in terms
ofvariant sequencespresent in otherwiseconserveddomains
in NBDs. It is established that each unique substitution in
CaCdr1p and by extension of other fungal ABC transporters
have dedicated role in ATP binding and hydrolysis and,
thus, are essential for drug eﬄux. Why fungal transporters
alone have evolved and retained these divergent domain
based amino acid substitution is not understood. But these
uniqueresiduesalsoprovideanopportunitytodevelopnovel
modulators or inhibitors of these eﬄux pump proteins.
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